HUB Investment Partners LLC Makes New $219,000 Investment in Integer Holdings Co. (NYSE:ITGR)

HUB Investment Partners LLC bought a new position in shares of Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,653 shares of the medical equipment provider’s stock, valued at approximately $219,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mather Group LLC. grew its holdings in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 143 shares during the period. R Squared Ltd purchased a new position in shares of Integer during the 4th quarter worth approximately $44,000. Versant Capital Management Inc grew its holdings in shares of Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 183 shares during the period. Principal Securities Inc. grew its holdings in shares of Integer by 31.2% during the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 152 shares during the period. Finally, Contravisory Investment Management Inc. grew its holdings in shares of Integer by 210.8% during the 4th quarter. Contravisory Investment Management Inc. now owns 693 shares of the medical equipment provider’s stock worth $92,000 after acquiring an additional 470 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Truist Financial boosted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Citigroup boosted their price target on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. KeyCorp boosted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Benchmark boosted their price target on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Integer presently has an average rating of “Moderate Buy” and a consensus price target of $149.00.

Integer Stock Performance

ITGR stock opened at $115.07 on Friday. The stock has a market capitalization of $3.87 billion, a PE ratio of 34.25, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $132.59 and its 200 day simple moving average is $132.35.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. As a group, research analysts forecast that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.